B
EWTX icon

Braidwell’s Edgewise Therapeutics EWTX Stock Holding History

Braidwell’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.1M Sell
1,996,965
-350,618
-15% -$12.1M 3% 4
2026
Q1 		$73.9M Sell
2,347,583
-2,863,248
-55% -$82.6M 2.47% 10
2025
Q4 		$129M Hold
5,210,831
– – 4.14% 3
2025
Q3 		$84.5M Hold
5,210,831
– – 2.51% 13
2025
Q2 		$68.3M Buy
5,210,831
+2,752,023
+112% +$39.7M 2.34% 16
2025
Q1 		$54.1M Buy
2,458,808
+126,612
+5% +$3.32M 1.9% 23
2024
Q4 		$62.3M Buy
2,332,196
+373,886
+19% +$11.9M 1.85% 19
2024
Q3 		$52.3M Buy
+1,958,310
New +$39M 1.48% 29

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Braidwell's EWTX Position: Q2 2026 in Review

Braidwell reduced its Edgewise Therapeutics (EWTX) stake by 15% in Q2 2026, selling an estimated $12.1M and leaving 1,996,965 shares worth $81.1M. The position accounts for 3% of the portfolio, ranked #4.

Braidwell first reported a position in EWTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $129M in Q4 2025. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Braidwell held 1,996,965 shares of Edgewise Therapeutics worth $81.1M as of Q2 2026.
  • Braidwell sold 350,618 Edgewise Therapeutics shares in Q2 2026, an estimated $12.1M.
  • Edgewise Therapeutics made up 3% of Braidwell's portfolio in Q2 2026, its #4 holding.
  • Braidwell first reported a position in Edgewise Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Braidwell's Edgewise Therapeutics position peaked at $129M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.